Skip to main content
森萱医药 logo

森萱医药 — Investor Relations & Filings

Ticker · 920946 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 417 across all filing types
Latest filing 2023-03-28 Governance Information
Country CN China
Listing Beijing Stock Exchange 920946

About 森萱医药

https://www.senxuan.cn/

Jiangsu Senxuan Pharmaceutical Co., Ltd. specializes in the research, development, and production of pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and specialized fine chemicals. The company’s product portfolio includes key intermediates for antiviral medications, such as those used in the treatment of HIV, and anticonvulsant agents like Primidone. Additionally, it produces high-purity chemical solvents including 1,4-dioxane and 1,3-dioxolane for diverse industrial applications. Senxuan Pharmaceutical maintains a focus on advanced chemical synthesis and large-scale manufacturing capabilities, adhering to international quality standards to support the global life sciences and chemical sectors. Its operations are characterized by a commitment to technical innovation and the supply of critical chemical building blocks for complex therapeutic formulations.

Recent filings

Filing Released Lang Actions
信息披露管理制度
Governance Information Classification · 95% confidence The document is a detailed disclosure of the company's information disclosure management system, including rules and procedures for periodic reports (annual, interim, quarterly), temporary reports, board and shareholder meeting resolutions, transaction disclosures, related party transactions, and other significant events. It references regulatory requirements from the China Securities Regulatory Commission and Beijing Stock Exchange, and outlines the content and timing of annual reports, interim reports, and other disclosures. The document is not itself an annual report or interim report but a governance and procedural document about information disclosure. It does not contain financial statements or earnings data but rather the framework for disclosures. Therefore, it fits best under Governance Information (CGR), which covers internal rules, board structure, and governance practices related to disclosures.
2023-03-28 Chinese
关于使用闲置募集资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Jiangsu Senxuan Pharmaceutical Co., Ltd. regarding the use of idle raised funds for cash management. It details the original fundraising, the use and storage of the funds, the investment products for cash management, decision-making and risk control measures, and includes opinions from independent directors, the supervisory board, and the sponsoring institution. The document does not contain financial statements or comprehensive financial data but rather describes a financing activity update and related approvals. It is not a full financial report, audit, or earnings release. The document is a specific update on capital usage and financing activities related to raised funds. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is under 5,000 characters but contains substantive content about financing usage, not just a report publication announcement or regulatory filing. Hence, the classification is CAP with high confidence.
2023-03-28 Chinese
2022年度独立董事述职报告
Regulatory Filings Classification · 95% confidence The document is titled '2022 年度独立董事述职报告' which translates to '2022 Annual Independent Directors' Report'. It details the attendance and activities of independent directors during the year 2022, including their opinions on various company matters, supervision of information disclosure, and protection of investor rights. The content focuses on the independent directors' duties and their report on their work during the year. It is not a full annual report (10-K), audit report, or financial statement, but rather a specific report by independent directors on their activities and opinions. This type of document is best classified under Regulatory Filings (RNS) as it is a regulatory disclosure related to corporate governance and director duties but does not fit the other more specific categories like Board/Management Information (MANG) which is for changes in board or management, or Governance Information (CGR) which is about governance rules and structure. The document length is 2343 characters, relatively short and focused on a specific report by independent directors, consistent with RNS filings. Confidence is high due to clear document title and content focus.
2023-03-28 Chinese
2022年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "专项报告" (special report) on the storage and actual use of raised funds (募集资金存放与实际使用情况的专项报告) by 江苏森萱医药股份有限公司. It details the issuance of shares, the amount of funds raised, the use of those funds, the management and supervision of the funds, and includes audit and verification opinions from accounting and sponsoring institutions. The document references regulatory approvals and compliance with securities laws and stock exchange rules. It is a detailed report on the use and management of capital raised through a public offering, including specifics on fund allocation, usage, and balance. This type of document is a specialized report on capital raising and fund usage, which aligns with the category "Capital/Financing Update (CAP)". It is not a full annual or interim report, nor is it an announcement or certification. The length and detail confirm it is a substantive report on capital usage.
2023-03-28 Chinese
2022年度非经营性资金占用及其他关联资金占用的专项说明
Audit Report / Information Classification · 95% confidence The document is a special explanatory statement regarding non-operating fund occupation and other related party fund transactions for Jiangsu Senxuan Pharmaceutical Co., Ltd. for the year 2022. It references an audit report issued by Tianheng Certified Public Accountants and complies with disclosure requirements of the Beijing Stock Exchange. The document includes detailed financial data and audit verification related to these specific fund transactions, not a full annual report or interim report. It is a standalone audit-related statement focusing on a particular aspect of the company's financials, consistent with an Audit Report / Information filing rather than a full Annual Report or other categories. The document length (6965 characters) and content support classification as an Audit Report / Information (AR).
2023-03-28 Chinese
会计政策变更公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Jiangsu Senxuan Pharmaceutical Co., Ltd. regarding changes in accounting policies effective from January 1, 2023. It details the nature of the accounting policy changes, reasons for the changes, and opinions from the board and supervisory committee. The document does not contain financial statements or detailed financial data but rather explains the policy change and its impact. It is a regulatory announcement about accounting policy changes, not a full financial report or audit report. Given the content and length (1632 characters), it fits best as a Regulatory Filing (RNS) rather than an Annual Report, Audit Report, or Interim Report. It is not a report publication announcement since it contains substantive information about the policy change itself.
2023-03-28 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.